1128 related articles for article (PubMed ID: 22579621)
21. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W
Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271
[TBL] [Abstract][Full Text] [Related]
22. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
23. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
25. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
Zhang X; Zhang J; Tong L; Luo Y; Su M; Zang Y; Li J; Lu W; Chen Y
Bioorg Med Chem; 2013 Jun; 21(11):3240-4. PubMed ID: 23602523
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Pabba C; Gregg BT; Kitchen DB; Chen ZJ; Judkins A
Bioorg Med Chem Lett; 2011 Jan; 21(1):324-8. PubMed ID: 21109435
[TBL] [Abstract][Full Text] [Related]
27. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors.
Zhang S; Huang W; Li X; Yang Z; Feng B
Chem Biol Drug Des; 2015 Oct; 86(4):795-804. PubMed ID: 25763653
[TBL] [Abstract][Full Text] [Related]
29. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Thuan NT; Huong LT; Park EJ; Young Ji A; Soon Kang J; Phuong Dung PT; Han SB; Nam NH
Chem Biodivers; 2019 Apr; 16(4):e1800502. PubMed ID: 30653817
[TBL] [Abstract][Full Text] [Related]
30. Design and synthesis of novel isoxazole-based HDAC inhibitors.
Conti P; Tamborini L; Pinto A; Sola L; Ettari R; Mercurio C; De Micheli C
Eur J Med Chem; 2010 Sep; 45(9):4331-8. PubMed ID: 20637529
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Han L; Wang L; Hou X; Fu H; Song W; Tang W; Fang H
Bioorg Med Chem; 2014 Mar; 22(5):1529-38. PubMed ID: 24525003
[TBL] [Abstract][Full Text] [Related]
32. Novel inhibitors of human histone deacetylases: design, synthesis and bioactivity of 3-alkenoylcoumarines.
Seidel C; Schnekenburger M; Zwergel C; Gaascht F; Mai A; Dicato M; Kirsch G; Valente S; Diederich M
Bioorg Med Chem Lett; 2014 Aug; 24(16):3797-801. PubMed ID: 25042254
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
Kim DK; Lee JY; Kim JS; Ryu JH; Choi JY; Lee JW; Im GJ; Kim TK; Seo JW; Park HJ; Yoo J; Park JH; Kim TY; Bang YJ
J Med Chem; 2003 Dec; 46(26):5745-51. PubMed ID: 14667227
[TBL] [Abstract][Full Text] [Related]
34. Structure-based optimization of click-based histone deacetylase inhibitors.
Hou J; Feng C; Li Z; Fang Q; Wang H; Gu G; Shi Y; Liu P; Xu F; Yin Z; Shen J; Wang P
Eur J Med Chem; 2011 Aug; 46(8):3190-200. PubMed ID: 21621883
[TBL] [Abstract][Full Text] [Related]
35. Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
Cincinelli R; Musso L; Giannini G; Zuco V; De Cesare M; Zunino F; Dallavalle S
Eur J Med Chem; 2014 May; 79():251-9. PubMed ID: 24742384
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.
Zhou M; Ning C; Liu R; He Y; Yu N
Bioorg Med Chem Lett; 2013 Jun; 23(11):3200-3. PubMed ID: 23639537
[TBL] [Abstract][Full Text] [Related]
37. Discovery of the first histone deacetylase 6/8 dual inhibitors.
Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB
J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxic effects of Jay Amin hydroxamic acid (JAHA), a ferrocene-based class I histone deacetylase inhibitor, on triple-negative MDA-MB231 breast cancer cells.
Librizzi M; Longo A; Chiarelli R; Amin J; Spencer J; Luparello C
Chem Res Toxicol; 2012 Nov; 25(11):2608-16. PubMed ID: 23094795
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and biological activity of hydroxamic tertiary amines as histone deacetylase inhibitors.
Terracciano S; Chini MG; Riccio R; Bruno I; Bifulco G
ChemMedChem; 2012 Apr; 7(4):694-702. PubMed ID: 22278987
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
